Scientists crispr patients' own immune cells in bid to shrink hard-to-treat gi tumors
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Last year, researchers at the University of Pennsylvania, led by immunotherapy pioneer Carl June, showed that it was safe and feasible to treat cancer patients with infusions of their own
immune cells that had been edited with the technology known as CRISPR. The trial was small, and the patients weren’t cured of their cancer. The study was designed only to test safety. Now,
however, a team at the University of Minnesota has infused CRISPR-edited immune cells into patients with advanced gastrointestinal cancers — in hopes the approach will actually shrink tumors
and help patients live longer. STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS IN-DEPTH ANALYSIS,
NEWSLETTERS, PREMIUM EVENTS, AND NEWS ALERTS. Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe